Natural bioactive compounds: antibiotics by Dezfully, N. Khandan & Heidari, A.
Journal of Fundamental and Applied Sciences is licensed under a Creative Commons Attribution-NonCommercial 4.0
International License. Libraries Resource Directory. We are listed under Research Associations category.
NATURAL BIOACTIVE COMPOUNDS: ANTIBIOTICS
N. Khandan Dezfully1,2,* and A. Heidari3
1Department of Studies in Microbiology, University of Mysore, Manasagangotri, Mysore-
570006, Karnataka, India
2Young Researchers and Elite Club, Karaj Branch, Islamic Azad University, Alborz, Iran
3Department of Emergency Medicine, Shahid Beheshti Medical University, Tehran, Iran
Published online: 13 June 2016
ABSTRACT
Antibiotics are powerful therapeutic agents that are produced by diverse living
organisms. Over the last several decades, natural bioactive products particularly
antibiotics have continued to play a significant role in drug discovery and has
expanded the process for developing drugs with high degree of therapeutic index and
specific action. Today, there is an alarming deficiency of new antibiotics in the
pharmaceutical industry that could be due to the emergence of antibiotic resistance
properties of some pathogens, toxicity and undesirable side effects of some used
antibiotics. Although much progress has been performed in the field of chemical synthesis
and engineered biosynthesis of antimicrobial compounds. Hence, there is a need in
approach for novel antibiotics and research to improve the safety as well as therapeutic
efficiency of the discovered bioactive compounds as part of the strategy to control the
emerging drug-resistant pathogens in research programme around the world. This article
reviews the history of antibiotics, different types of antibiotics, mechanisms of antibiotic
action and new challenges in antibiotics.
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1. INTRODUCTION
Antibiotics are the most  important class of  natural  bioactive  compounds  (as  a  secondary
metabolites) with low molecular  weight  (MW  3000)  which  are  produced by  or  derived
from diverse  organisms  (bacteria,  actinomycetes,  fungi, algae,  lichens,  green    plants,
etc.) by fermentation, which  have the capacity of   inhibiting  or  terminating  total  metabolic
cell activity [1-3]. The word antibiotic came from the Greek word antibiosis (Gr.  anti,
"against";  bios,  "life")  a term coined  by  Louis  Pasteur's  pupil  Paul  Vuillemin in  1889.
They are defined as a chemical substance that either inhibits the growth of or destroys
microorganisms. These natural compounds can show either antimicrobial (antibacterial,
antifungal, antiprotozoal), antiviral and antitumor activities. They considered as ‘bioactive
compounds’ because they have biological activity. Antimicrobial compounds are classified
based on the range of effectiveness in to broad spectrum that are (effective against many types
of microorganism) and narrow spectrum (effective against a limited group of microorganism)
[1]. Antibiotics have been used in a variety of  industries  such  as  pharmaceuticals [4] and
food  industry  ,  especially  in  the  field of prebiotics  and probiotics [3, 5]. This review
outlines the history of antibiotics, different types of antibiotics, the mechanism of antibiotics
action and new challenges in antibiotics.
2. HISTORY OF ANTIBIOTICS
Since the beginning of human suffering from infectious diseases caused by microorganisms,
the search for solutions started and leads to discover of wide range of antibiotics from
microorganisms such as actinomycetes [6, 7]. Thus, the microorganisms have made
prominent contributions to the health and well-being of people throughout the world [8, 9].
Although  penicillin  was  the  first  antibiotic,  discovered by Alexander Fleming in 1928, but
it was not until the early 1940s that its true potential was acknowledged  and  large  scale
fermentation  processes  were  developed  for  the  production  of antibiotics. Waksman and
Schatz (1945) isolated streptomycin as a first aminoglycoside against tuberculosis and a
number of other antibiotics from Streptomyces griseus [10, 11]. After the revolution in the
“heroic” or “golden era”, in the forties and early fifties, when nearly all groups of important
antibacterial antibiotics (tetracyclines, cephalosporins, aminoglycosides, and macrolides)
were discovered, the story of successfully continued [12]. It seemed that in the fifties and
sixties that the main problems of chemotherapy had been solved.  During  this  period  the
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discovery  of  antitumor [13],  antiviral  and  non  antibiotic  enzyme  inhibitory
metabolites[14, 15] had just started [16].
In  the  next  period,  between  seventies  and  nineties  the  efficiency  of  research  had
decreased because  of  increase  in  the  cost of  research.  Despite the  high  cost of  research
the  number  of discovered  new  compounds  still  increased and  was  mainly  analogue  of
known  compounds.  The  scope  of  search  for  various  bioactive  microbial  products  had,
however,  broadened.  The exploration  and  wide  utilization  of  antitumor  (doxorubicin)
and  agricultural  antibiotics (antiparasitic ,  monensin, avermectin and glufosinate),  the
preliminary discoveries  and  utilization  of  microbial  metabolites  in  the  pharmacological
fields (cyclosporin, statins), were  important  new  features [16 -18]. After  these  years,  from
the  nineties,  the  exponential  increase  in  the  number  of  new metabolites  (mainly  non-
antibiotic  compounds,  analogous  and  minor  compounds),  still continued but the
occurrence of new chemical types diminished. Due to urgent clinical needs, the  increasing
serious  problems  of  chemotherapy  (multi  drug-resistant  strains,  reappearing
mycobacterium, HIV, etc.),  new  challenges  in  the  therapy  of  physiological  diseases  and
in agriculture, the modernization of classical screening methods, allowed  by the  new
technologies, were highly required [19, 20]. The screenings have become more efficient than
ever. The dramatic  increase  in the isolation of  non-antibiotic  compounds  with activities in
pharmacological  and  agricultural fields increased  the share of various fungal metabolites
and the chemical synthesis of more intricate structures were  the  most  characteristic
features  of  this  period. Although,  antibiotics  have revolutionized  medical  care  in  the
20th century, It seems, with the beginning of the 21st Century, a new era of antibiotic research
had opened [16, 21].
The number of antibiotics were known in 1940 about 10~20, in 1950, 300~400, already
800~1000 in 1960 and approximately 2500 till 1970. Since then the  number  of all known
bioactive  microbial metabolites had doubled  in  every  ten  years.  In 1980 about 5,000 and
in 1990 about 10,000 antibiotic compounds were known [16]. The results of an extensive
research revealed that the total number of antibiotic compounds, recognized until now, is
around 25,000~ 30,000 (Figure 1). Beside plants [22], microorganisms represent a good
source of varied antibiotics. As, about 16,500 of antibiotics are extracted from
microorganisms. Among them, over 8,700 (53 %) antibiotics are produced by Actinobacteria,
4,900 (30 %) by fungi and 2,900 (18 %) by unicellular bacteria [8, 16]. The Approximate
number of known antibiotics produced by living organisms is presented in Table 1.
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Table 1. Approximate number  of  known  bioactive  natural  products  from  living
organisms
Source:
Adopted from Berdy, 2005
2.1. Classification of antibiotics
The  great   number  of  diverse  antibiotics can  be  classified  in  different   ways  based  on
microbial  spectrum, the  type  of  biological  activity  and  the  chemical  structure. But   they
are  usually  classified  based  on their  structure  and/or  function [ 1,3, 23]. The major
classes are as follows:
a) ß-Lactams (Penicillins, Cephalosporins, Monobactams and Carbapenems)










Algae, Lichens ~ 1000
Higher Plants 10,000
to12,000
Animal Kingdom ~ 5000
Protozoa ~ 50
Invertebrates ~ 500
Marine animals 3000 to 4000
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e) Macrolides (Erythromycin and Quinines)
f) Glycopeptides (Vancomycin)
2.2. Mechanism of antibiotic action
Antimicrobial  agents  are  broadly  classified  based  on  in vitro behavior  as  microcidal
(kill microorganisms directly)  or  microstatic  (simply  prevent  them  from  growth). The
major modes of action by different antibiotics include [1, 23]:
1) Inhibition of Cell wall synthesis
The antibiotics such as ß– lactams (penicillin, cephalosporins) and glycopeptides
(vancomycine and teicoplanin) block the ability of bacteria to synthesize their cell wall by
inhibiting the synthesis of peptidoglycan.
2) Plasma membrane inhibition
Certain antibiotics, especially polypeptide antibiotics, bring about changes in the permeability
of  the  plasma  membrane;  these  changes  result  in  the  loss  of  important  metabolites
from  the microbial cell. As for example polymixin B binds to the phospholipids of the cell
membrane and  disrupts  its  integrity,  destroying  their  ability  to  function  as  osmotic
barriers.
3) Inhibition of nucleic acid synthesis
A  number  of  antibiotics  interfere  with  nucleic  acid  metabolism  of  microorganisms.
ciprofloxacine,  nalidixic  acid,  rifamycin,  trimethoprime,  oxolinic  acid,  etc.  bind  to
DNA gyrase  (topoisomerase)  thereby  preventing  the  supercoiling of  DNA,  and
inhibiting  DNA synthesis.  They  are  widely  used  in  chemotherapy  because  they  are
more  selective toxicity.
4) Inhibition of protein synthesis
The ribosomes are the sites of protein synthesis in the bacterial cell. Prokaryotic  cells  have
70S  ribosome  which  is  made  up  50S  and  30S  unit.  Antibiotics  such  as  streptomycin  ,
gentamycin,  kanamycine,  tetracycline,  spectinomycine,  chloramphenicol,  and
erythromycin bind  to  either  50S  or  30S  subunit  of  the  ribosome or  to  mRNA  and
impair  the functioning.There  by  inhibiting the  synthesis  of  proteins.
5) Inhibition of enzymatic activity
Sulfonamides  completely  inhibit  the  important  metabolic  pathways  (synthesis  of  folic
acid)occurring inside the bacterial cell. Thus, important metabolites like folic acid, a vitamin
that  functions  as  a  coenzyme  for  the  synthesis  of  the  purine  and  pyrimidine  base  of
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nucleic acids,which the  bacteria  have to produce within their cells to survive are not
produced.
3. DRUG RESISTANCE IN MICROBES
Although, antimicrobial agents represent one of the essential therapeutic tools, both in human
and veterinary medicine to control and treat a variety of microbial infectious diseases.
However, during  the  past  five  decades  the  use  and  sometimes  misuse  of  antimicrobials
has  caused bacterial  resistance  to  currently  available  antibacterial  drugs  by  either  new
mutations  or the exchange  of  genetic  information  that is,  placing past resistance  genes
into new hosts[24].
Several  mechanisms  of  antimicrobial  resistance  are  easily spread  to  a  variety  of
bacterial genera [25, 26]:
A) Genetic resistance: this occurs due to chromosomal mutations or acquisition of antibiotic
resistant genes on plasmids or transposons.
B)  Phenotypic resistance: this occurs due to changes in bacterial physiological state in
stationary phase.
The main phenotypic antimicrobial resistance is as follows:
a)  Enzymatic inactivation like ß-lactams, Aminoglycosides and Macrolides.
b)  Decreased permeability/uptake like ß -lactams and Aminoglycosides
c)  Enhanced efflux like Tetracycline, Quinolones and Macrolides.
d)  Alteration of drug target site due to change in antibiotic  binding target site like of ß-
lactamase,  Quinolones,  Aminoglycosides,  Vancomycin,  Macrolides  and
TMP/ SMX.
4. NEW CHALLENGES IN ANTIBIOTICS
Today, over 30,000 clinical diseases described. Under a third of these could be treated
symptomicaly and just a few can be cured. Despite the developments and progress made in
modern medicine, science and biotechnology, infectious diseases are still the second leading
cause of death worldwide [27, 28]. It is an epidemic of multiple antibiotic resistance in
pathogens has been described in various fields,  including  but  not  limited  to  a  global
pandemic  of  methicillin-resistant Staphylococcus  aureus (MRSA)  infection [29]. The
global  spread  of  antibiotic  resistance properties among common  respiratory  pathogens
such  as Streptococcus  pneumoniae and Mycobacterium tuberculosis and  epidemic  in
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Vancomycin  Resistant  Enterococci  (VRE), Pseudomonas aeruginosa and Candida
albicans, etc. Infections caused by these and other antibiotic-resistant microorganisms have
given effect and significant impact on morbidity and mortality, which has become a major
clinical and public health problem in the 21st century [30-32]. According  to  World  Health
Organization (WHO),  over-prescription  and incorrect use of antibiotics leads to the
generation  of  antibiotic  resistance  in  many  human  pathogens.  The  slogan  of WHO in
2011 was “multi- drug  resistant  pathogens  have become  a  major  global  healthcare threat”
[21]. Moreover, the  undesirable  side  effects  and  toxicity  of  some  used antibiotics
(Ningthoujam  et  al,  2009), non-cultivable of some species of  potent bacteria [33] and  the
exhaustion  of  the natural sources dictate an increasing necessity of survey for unexplored
and under-explored niche habitats for the isolation and discovery  of  natural  product-based
drugs  with  broad-spectrum  which  possess  different  mechanisms  of  action  and  which
are  free  from  undesirable side  effects  (safe) [24] Such  things  be  developed  as  part of
the  strategy  to  control  the  emerging drug-resistant  pathogens  in  research programs
around the  world [32, 34-36]. Hence, there is a need for more and more screening programs
in isolation of new potent organisms and  novel antimicrobial metabolites  from  newer
ecosystem    for  potential pharmaceutical,  agriculture  and  industrial  applications  around
the world [37-45].
5. CONCLUSION
Antibiotics are secondary metabolites with powerful therapeutic activity which are produced
by potent living organisms. In  recent  times,  the drug  resistant  strains  of microorganisms
emerge  more  quickly  than  the  rate  of  discovery  of  new  drugs  and antibiotics. Hence
the search for isolating novel antibiotics continues to be of immense importance in research
programs around the world for pharmaceutical, industrial and agricultural applications.
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